{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:22:43Z","timestamp":1789179763106,"version":"build-2803163510"},"reference-count":59,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:00:00Z","timestamp":1767916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","award":["7R01CA269223"],"award-info":[{"award-number":["7R01CA269223"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.dmd.2026.100235","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:06:25Z","timestamp":1768320385000},"page":"100235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Inhibitory effects of \u03948-tetrahydrocannabinol on nicotine metabolism and implications as a smoking cessation agent"],"prefix":"10.1016","volume":"54","author":[{"given":"Mengqi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2435-5610","authenticated-orcid":false,"given":"Shaman","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dmd.2026.100235_bib1","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12916-020-01677-9","article-title":"Global burden of disease due to smokeless tobacco consumption in adults: an updated analysis of data from 127 countries","volume":"18","author":"Siddiqi","year":"2020","journal-title":"BMC Med"},{"key":"10.1016\/j.dmd.2026.100235_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.addicn.2023.100103","article-title":"New medications development for smoking cessation","volume":"7","author":"Lengel","year":"2023","journal-title":"Addict Neurosci"},{"key":"10.1016\/j.dmd.2026.100235_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100722","article-title":"Biochemistry of nicotine metabolism and its relevance to lung cancer","volume":"296","author":"Murphy","year":"2021","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.dmd.2026.100235_bib5","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/FPC.0b013e32835f834d","article-title":"CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers","volume":"23","author":"Chenoweth","year":"2013","journal-title":"Pharmacogenet Genomics"},{"issue":"5","key":"10.1016\/j.dmd.2026.100235_bib6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/ntr\/ntab175","article-title":"Nicotine metabolism predicted by CYP2A6 genotypes in relation to smoking cessation: a systematic review","volume":"24","author":"Jones","year":"2022","journal-title":"Nicotine Tob Res"},{"issue":"3","key":"10.1016\/j.dmd.2026.100235_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/17425255.2021.1863948","article-title":"Pharmacogenetics factors influencing smoking cessation success; the importance of nicotine metabolism","volume":"17","author":"Perez-Paramo","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"10.1016\/j.dmd.2026.100235_bib8","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/jnci\/94.2.108","article-title":"Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans","volume":"94","author":"Benowitz","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.dmd.2026.100235_bib9","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/ntr\/ntab064","article-title":"Impact of CYP2A6 activity on nicotine reinforcement and cue-reactivity in daily smokers","volume":"23","author":"Butler","year":"2021","journal-title":"Nicotine Tob Res"},{"issue":"11","key":"10.1016\/j.dmd.2026.100235_bib10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1359-6446(03)02704-1","article-title":"Decreasing smoking behaviour and risk through CYP2A6 inhibition","volume":"8","author":"Sellers","year":"2003","journal-title":"Drug Discov Today"},{"issue":"1","key":"10.1016\/j.dmd.2026.100235_bib11","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1067\/mcp.2000.107651","article-title":"Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking","volume":"68","author":"Sellers","year":"2000","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.dmd.2026.100235_bib12","article-title":"Inhibitory effects of \u03948-tetrahydrocannabinol on major hepatic cytochrome P450 enzymes and implications for drug disposition","volume":"53","author":"Zhao","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2026.100235_bib13","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.121.000442","article-title":"Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmd.2026.100235_bib14","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1124\/dmd.121.000530","article-title":"Inhibition of UDP-glucuronosyltransferase enzymes by major cannabinoids and their metabolites","volume":"49","author":"Nasrin","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100235_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1021\/acs.chemrestox.2c00259","article-title":"Inhibition of nicotine metabolism by cannabidiol (CBD) and 7-hydroxycannabidiol (7-OH-CBD)","volume":"36","author":"Nasrin","year":"2023","journal-title":"Chem Res Toxicol"},{"issue":"9","key":"10.1016\/j.dmd.2026.100235_bib16","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.addbeh.2013.03.011","article-title":"Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings","volume":"38","author":"Morgan","year":"2013","journal-title":"Addict Behav"},{"issue":"2","key":"10.1016\/j.dmd.2026.100235_bib17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/02791072.2023.2200211","article-title":"Delta-8- and delta-9-THC use frequency, use motives, and mental health outcomes","volume":"56","author":"Pellicane","year":"2024","journal-title":"J Psychoactive Drugs"},{"issue":"10","key":"10.1016\/j.dmd.2026.100235_bib18","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/jama.2024.0865","article-title":"Adolescent delta8-THC and marijuana use in the US","volume":"331","author":"Harlow","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.dmd.2026.100235_bib19","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s42238-021-00115-8","article-title":"Delta-8-THC: delta-9-THC's nicer younger sibling?","volume":"4","author":"Kruger","year":"2022","journal-title":"J Cannabis Res"},{"issue":"10","key":"10.1016\/j.dmd.2026.100235_bib20","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1124\/dmd.120.000073","article-title":"Predicting the potential for cannabinoids to precipitate pharmacokinetic drug interactions via reversible inhibition or inactivation of major cytochromes P450","volume":"48","author":"Bansal","year":"2020","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100235_bib21","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/cpt.2973","article-title":"Evaluation of cytochrome P450-mediated cannabinoid-drug interactions in healthy adult participants","volume":"114","author":"Bansal","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100235_bib22","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.0306-5251.2001.01500.x","article-title":"Polymorphisms of CYP2A6 and its practical consequences","volume":"52","author":"Raunio","year":"2001","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100235_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3390\/jpm7040018","article-title":"Variation in CYP2A6 activity and personalized medicine","volume":"7","author":"Tanner","year":"2017","journal-title":"J Pers Med"},{"issue":"5","key":"10.1016\/j.dmd.2026.100235_bib24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.clpt.2006.08.011","article-title":"CYP2A6 genotype and the metabolism and disposition kinetics of nicotine","volume":"80","author":"Benowitz","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dmd.2026.100235_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.clpt.6100246","article-title":"Identification of novel CYP2A6\u22171B variants: the CYP2A6\u22171B allele is associated with faster in vivo nicotine metabolism","volume":"83","author":"Mwenifumbo","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100235_bib26","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.tpj.6500348","article-title":"CYP2A6 polymorphisms are associated with nicotine dependence and influence withdrawal symptoms in smoking cessation","volume":"6","author":"Kubota","year":"2006","journal-title":"Pharmacogenomics J"},{"issue":"Pt 1","key":"10.1016\/j.dmd.2026.100235_bib27","article-title":"Non-additivity of the functional properties of individual P450 species and its manifestation in the effects of alcohol consumption on the metabolism of ketamine and amitriptyline","volume":"230","author":"Ponraj","year":"2024","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100235_bib28","doi-asserted-by":"crossref","first-page":"7550","DOI":"10.1038\/s41467-024-51947-w","article-title":"Genome-wide analyses of neonatal jaundice reveal a marked departure from adult bilirubin metabolism","volume":"15","author":"Sole-Navais","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.dmd.2026.100235_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2024.153903","article-title":"Drug-induced enzyme activity inhibition and CYP3A4 genetic polymorphism significantly shape the metabolic characteristics of furmonertinib","volume":"507","author":"Zhou","year":"2024","journal-title":"Toxicology"},{"issue":"4","key":"10.1016\/j.dmd.2026.100235_bib30","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/cpt.690","article-title":"Worldwide distribution of cytochrome P450 alleles: a meta-analysis of population-scale sequencing projects","volume":"102","author":"Zhou","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.dmd.2026.100235_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100104","article-title":"Identification of human hepatic UDP-glucuronosyltransferases involved in the glucuronidation of temazepam","volume":"53","author":"Bardhi","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2026.100235_bib32","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.3390\/biomedicines12081632","article-title":"Ganoderma lucidum polysaccharide peptide alleviates cyclophosphamide-induced male reproductive injury by reducing oxidative stress and apoptosis","volume":"12","author":"Zhang","year":"2024","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.dmd.2026.100235_bib33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1124\/dmd.123.001463","article-title":"Deciphering the role of fatty acid-metabolizing CYP4F11 in lung cancer and its potential as a drug target","volume":"52","author":"Jia","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100235_bib35","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1124\/dmd.121.000624","article-title":"CYP2C19 plays a major role in the hepatic N-oxidation of cotinine","volume":"51","author":"Perez-Paramo","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100235_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.314","article-title":"In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17\u03b2-dihydroexemestane","volume":"5","author":"Peterson","year":"2017","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"10.1016\/j.dmd.2026.100235_bib36","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.hansur.2016.12.007","article-title":"Rotational stability test for the diagnosis of radial collateral ligament rupture in the fingers: anatomical study","volume":"36","author":"Lazarus","year":"2017","journal-title":"Hand Surg Rehabil"},{"issue":"1","key":"10.1016\/j.dmd.2026.100235_bib37","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/biom14010099","article-title":"A review of CYP-mediated drug interactions: mechanisms and in vitro drug-drug interaction assessment","volume":"14","author":"Lee","year":"2024","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.dmd.2026.100235_bib38","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1124\/dmd.119.086470","article-title":"Quantifying hepatic enzyme kinetics of (-)-\u0394(9)-tetrahydrocannabinol (THC) and its psychoactive metabolite, 11-OH-THC, through in vitro modeling","volume":"47","author":"Patilea-Vrana","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2026.100235_bib39","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1208\/s12249-016-0672-2","article-title":"Ocular disposition of \u0394(8)-tetrahydrocannabinol from various topical ophthalmic formulations","volume":"18","author":"Punyamurthula","year":"2017","journal-title":"AAPS PharmSciTech"},{"issue":"5","key":"10.1016\/j.dmd.2026.100235_bib41","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1124\/dmd.105.008672","article-title":"The human intestinal cytochrome P450 \"pie\"","volume":"34","author":"Paine","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmd.2026.100235_bib42","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/clpt.1994.169","article-title":"Metabolism of nicotine to cotinine studied by a dual stable isotope method","volume":"56","author":"Benowitz","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"192","key":"10.1016\/j.dmd.2026.100235_bib43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/978-3-540-69248-5_2","article-title":"Nicotine chemistry, metabolism, kinetics and biomarkers","author":"Benowitz","year":"2009","journal-title":"Handb Exp Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100235_bib44","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1124\/dmd.115.067942","article-title":"Inactivation of CYP2A6 by the dietary phenylpropanoid trans-cinnamic aldehyde (cinnamaldehyde) and estimation of interactions with nicotine and letrozole","volume":"44","author":"Chan","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100235_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2025.112676","article-title":"A within-subject cross-over trial comparing the acute effects of oral delta-8-tetrahydrocannabinol and delta-9-tetrahydrocannabinol in healthy adults","volume":"272","author":"Zamarripa","year":"2025","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.dmd.2026.100235_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100135","article-title":"UGT2B7 mediated drug-drug interaction between cannabinoids and hydromorphone","volume":"53","author":"Coates","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100235_bib48","first-page":"66","article-title":"The role of metabolites in predicting drug-drug interactions: focus on irreversible cytochrome P450 inhibition","volume":"13","author":"VandenBrink","year":"2010","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"2","key":"10.1016\/j.dmd.2026.100235_bib49","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3390\/pharmaceutics16020243","article-title":"Cannabinoid-induced stereoselective inhibition of R-S-oxazepam glucuronidation: cannabinoid-oxazepam drug interactions","volume":"16","author":"Bardhi","year":"2024","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.dmd.2026.100235_bib50","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3390\/pharmaceutics16030418","article-title":"Cannabinoid-induced inhibition of morphine glucuronidation and the potential for in vivo drug-drug interactions","volume":"16","author":"Coates","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.dmd.2026.100235_bib51","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.drugalcdep.2015.01.032","article-title":"Association of CYP2A6 gene polymorphisms with cigarette consumption: a meta-analysis","volume":"149","author":"Pan","year":"2015","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"10.1016\/j.dmd.2026.100235_bib52","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/cpt.2259","article-title":"Do inhibitory metabolites impact DDI risk assessment? Analysis of in vitro and in vivo data from NDA reviews between 2013 and 2018","volume":"110","author":"Steinbronn","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.dmd.2026.100235_bib53","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/dmd.121.000505","article-title":"Tetrahydrocannabinol and its major metabolites are not (or are poor) substrates or inhibitors of human P-glycoprotein [ATP-binding cassette (ABC) B1] and breast cancer resistance protein (ABCG2)","volume":"49","author":"Chen","year":"2021","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100235_bib54","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1021\/acs.chemrestox.6b00387","article-title":"Nicotine metabolism and smoking: ethnic differences in the role of P450 2A6","volume":"30","author":"Murphy","year":"2017","journal-title":"Chem Res Toxicol"},{"issue":"12","key":"10.1016\/j.dmd.2026.100235_bib55","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1080\/17512433.2022.2148655","article-title":"Cannabinoids and drug metabolizing enzymes: potential for drug-drug interactions and implications for drug safety and efficacy","volume":"15","author":"Bardhi","year":"2022","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2026.100235_bib56","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0090-9556(25)06140-9","article-title":"Metabolic disposition of delta 8-tetrahydrocannabinol and its active metabolites, 11-hydroxy-delta 8-tetrahydrocannabinol and 11-oxo-delta 8-tetrahydrocannabinol, in mice","volume":"9","author":"Watanabe","year":"1981","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100235_bib57","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1208\/s12248-008-9042-7","article-title":"In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions","volume":"10","author":"Fowler","year":"2008","journal-title":"AAPS J"},{"key":"10.1016\/j.dmd.2026.100235_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116191","article-title":"CYP2C9, CYP3A and CYP2C19 metabolize Delta9-tetrahydrocannabinol to multiple metabolites but metabolism is affected by human liver fatty acid binding protein (FABP1)","volume":"228","author":"Yabut","year":"2024","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100235_bib59","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.123.001384","article-title":"Utility of physiologically based pharmacokinetic modeling in predicting and characterizing clinical drug interactions","volume":"53","author":"Foti","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2026.100235_bib60","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1124\/dmd.124.001477","article-title":"Differential tissue abundance of membrane-bound drug metabolizing enzymes and transporter proteins by global proteomics","volume":"52","author":"Singh","year":"2024","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2026.100235_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100138","article-title":"Regulation of hepatic organic anion transporting polypeptide 1B-type transport function by the protein kinase LYN","volume":"53","author":"Xu","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2026.100235_bib62","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1021\/acs.jmedchem.3c00514","article-title":"The importance of PK-PD","volume":"66","author":"Barrow","year":"2023","journal-title":"J Med Chem"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:20:05Z","timestamp":1774520405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626000048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0090955626000048"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100235","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibitory effects of \u03948-tetrahydrocannabinol on nicotine metabolism and implications as a smoking cessation agent","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100235","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100235"}}